SCbio: mRNA Ban Could Weaken S.C. Pandemic Readiness

SCbio President and CEO James Chappell, Ph.D., testified before the Medical and Health Affairs Subcommittee on Tuesday, January 20, opposing H. 4262.

What Is This Bill: H.4262 prohibits the administration of synthetic mRNA-based products for preventing communicable diseases in SC, with penalties for healthcare professionals—even if FDA-authorized in an emergency. This could delay or prevent access for SC residents (potentially requiring out-of-state travel), creating real challenges during a fast-moving threat. 

Why This Matters: This bill would prohibit the use of synthetic mRNA-based gene therapies that are used for contagious illnesses, like COVID-19. It introduces a one-year license suspension penalty for doctors who prescribe it in South Carolina.

SCbio’s View: SCbio strongly opposed the anti-mRNA vaccine bill and any proposed amendments to it, warning that the legislation in any form would seriously undermine South Carolina’s ability to respond to emerging health threats. The organization argued that the bill would pose unacceptable risks to public health while creating a chilling effect on mRNA research and innovation, ultimately jeopardizing the state’s life sciences sector. SCbio urged the committee to reject the bill outright.

What Happened: Thanks to advocacy from SCbio and strong collaboration with key stakeholders and experts, debate on this bill—which would restrict access to proven, life-saving mRNA-based therapies for treatment of infectious diseases—has been adjourned in subcommittee, where it remains.

What to Know: Benefits of mRNA Technology 

  • Proven track record: High efficacy in trials (over 94% for early COVID-19 versions), good safety profile (non-infectious, no live virus), and efficient, scalable production. 
  • Versatile and fast: “Plug-and-play” design enables quick updates for variants or new threats; cell-free manufacturing avoids bottlenecks. 
  • Broad potential: The technology could help prevent millions of deaths annually from preventable diseases and support ongoing research in our state’s life sciences ecosystem. 

On the Record:

“The vaccine is a life-changing technology that can treat a lot of diseases. It was chosen for a reason because it is a much faster option. You are looking at 3-4 months instead of 8-10-12 months for other vaccines. We don’t know if or when another pandemic may occur, so outright banning mRNA technologies for any vaccines for infectious diseases is a drastic measure that could put the entire population of S.C. at risk,” said Chappell.

“This is not a gene therapy like CRISPR, which makes double-strand breaks in your DNA to permanently edit or insert genetic material. mRNA vaccines do not alter, cut, or integrate into your DNA at all—they simply deliver temporary instructions to cells to produce a harmless protein, triggering an immune response before the mRNA is quickly degraded. mRNA tech is showing huge promise for treating cancer and other diseases, with personalized vaccines (like for melanoma and pancreatic cancer) advancing in trials and delivering strong immune responses. Banning mRNA vaccines could scare people away from these potentially life-saving treatments, slowing progress and hurting patients who need them most.”

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.